Form 4: Director Stephen Sherwin Exercises NBIX Stock Units

Neurocrine Biosciences Director Stephen A. Sherwin acquired 3,318 shares of common stock through the vesting of restricted stock units.

Summary

• Director Stephen A. Sherwin exercised 3,318 restricted stock units (RSUs) on May 21, 2026.
• The RSUs converted into 3,318 shares of Neurocrine Biosciences (NBIX) common stock at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership of common stock increased to 15,860 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard vesting of previously granted equity compensation rather than a discretionary market purchase or sale.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of insider equity movement.

Industry Context

StockSavvy.ai notes that routine RSU vesting for board members is a standard component of executive and director compensation packages in the biotechnology sector, signaling no change in strategic direction.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation in the pharmaceutical industry.
• The acquisition of shares by a director is consistent with typical retention and incentive structures seen in mid-to-large cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine compensation event.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Trading, Director Ownership, Restricted Stock Units